je.st
news
Amgen And AstraZeneca Announce Positive Results From Third And Final...
2014-11-26 10:28:14| Biotech - Topix.net
Amgen and AstraZeneca today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both StelaraA and placebo at week 12. Brodalumab 210 mg given every two weeks and the brodalumab weight-based analysis group were each shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index .
Tags: results
final
third
positive
Category:Biotechnology and Pharmaceuticals